Allogeneic stem cell transplantation benefits for patients ≥ 60 years with acute myeloid leukemia and FLT 3-ITD ; a study from the Acute Leukemia Working

247 words

[1]  C. Bloomfield,et al.  Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation , 2017, The New England journal of medicine.

[2]  M. Andreeff,et al.  Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation , 2017, American journal of hematology.

[3]  M. Levis,et al.  How I treat FLT3-mutated AML. , 2017, Blood.

[4]  Bob Löwenberg,et al.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.

[5]  C. Craddock,et al.  A comparison between allogeneic stem cell transplantation from unmanipulated haploidentical and unrelated donors in acute leukemia , 2017, Journal of Hematology & Oncology.

[6]  E. Vellenga,et al.  Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio , 2016, Leukemia.

[7]  B. Sandmaier,et al.  Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis , 2016, Cancer.

[8]  W. Hiddemann,et al.  Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. , 2016, Blood.

[9]  S. Nikiforow,et al.  Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3‐ITD acute myeloid leukaemia in first complete remission , 2016, British journal of haematology.

[10]  H. Kantarjian,et al.  Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[11]  Nicola D. Roberts,et al.  Genomic Classification and Prognosis in Acute Myeloid Leukemia. , 2016, The New England journal of medicine.

[12]  N. Schmitz,et al.  Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[13]  Jong-Ho Won,et al.  DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[14]  S. Jhanwar,et al.  Stem cell transplantation in adults with acute myelogenous leukemia, normal cytogenetics, and the FLT3-ITD mutation. , 2016, Leukemia research.

[15]  S. Miyano,et al.  Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse. , 2015, Blood.

[16]  J. Esteve,et al.  Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation. , 2015, Blood.

[17]  M. Aljurf,et al.  HLA Mismatch Is Associated with Worse Outcomes after Unrelated Donor Reduced-Intensity Conditioning Hematopoietic Cell Transplantation: An Analysis from the Center for International Blood and Marrow Transplant Research. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[18]  R. Mahfouz,et al.  Sorafenib Maintenance Appears Safe and Improves Clinical Outcomes in FLT3-ITD Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation. , 2015, Clinical lymphoma, myeloma & leukemia.

[19]  C. Meisner,et al.  Influence of age on outcome after allogeneic hematopoietic cell transplantation: a single center study in patients aged ⩾60 , 2015, Bone Marrow Transplantation.

[20]  E. Estey,et al.  Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. Sorror,et al.  Number of courses of induction therapy independently predicts outcome after allogeneic transplantation for acute myeloid leukemia in first morphological remission. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[22]  A. Lane,et al.  Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[23]  L. Bullinger,et al.  Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation. , 2014, Blood.

[24]  E. Estey,et al.  Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  R. Larson,et al.  Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients , 2014, Haematologica.

[26]  R. Hills,et al.  Impact of FLT3(ITD) mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia. , 2014, Blood.

[27]  J. Lipton,et al.  Benefit of allogeneic transplantation in patients age ≥ 60 years with acute myeloid leukemia is limited to those in first complete remission at time of transplant. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[28]  R. Hills,et al.  The prognostic relevance of flt3 and npm1 mutations on older patients treated intensively or non-intensively: a study of 1312 patients in the UK NCRI AML16 trial , 2014, Leukemia.

[29]  P. Armand,et al.  Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[30]  Benjamin J. Raphael,et al.  Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.

[31]  J. Esteve,et al.  Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy. , 2013, Blood.

[32]  R. Hills,et al.  Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Hwai I. Yang,et al.  Prognostic impact of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia patients with internal tandem duplication of FLT3. , 2013, Leukemia research.

[34]  K. van Besien,et al.  Pilot study of comprehensive geriatric assessment (CGA) in allogeneic transplant: CGA captures a high prevalence of vulnerabilities in older transplant recipients. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[35]  N. Kröger,et al.  Allogeneic stem cell transplantation for older advanced MDS patients: improved survival with young unrelated donor in comparison with HLA-identical siblings , 2013, Leukemia.

[36]  J. Rowe,et al.  The myth of the second remission of acute leukemia in the adult. , 2013, Blood.

[37]  J. Williamson,et al.  Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. , 2010, Blood.

[38]  M. Labopin,et al.  Potent graft-versus-leukemia effect after reduced-intensity allogeneic SCT for intermediate-risk AML with FLT3-ITD or wild-type NPM1 and CEBPA without FLT3-ITD. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[39]  K. Götze,et al.  High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses , 2012, Leukemia.

[40]  J. Esteve,et al.  Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  D. Neuberg,et al.  Outcome of older adults with cytogenetically normal AML (CN-AML) and FLT3 mutations. , 2011, Leukemia research.

[42]  P. Hari,et al.  Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. , 2011, JAMA.

[43]  M. McDevitt,et al.  Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[44]  T. Haferlach,et al.  Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia , 2011, Leukemia.

[45]  E. Vellenga,et al.  PROGNOSTIC IMPACT OF WHITE BLOOD CELL COUNT IN INTERMEDIATE RISK AML , 2011 .

[46]  Michael Boeckh,et al.  Reduced mortality after allogeneic hematopoietic-cell transplantation. , 2010, The New England journal of medicine.

[47]  M. Caligiuri,et al.  FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. , 2010, Blood.

[48]  Bob Löwenberg,et al.  Review Articles (434 articles) , 2008 .

[49]  G. Mufti,et al.  Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  B. Sandmaier,et al.  Defining the intensity of conditioning regimens: working definitions. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[51]  Axel Benner,et al.  Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. , 2008, The New England journal of medicine.

[52]  Adam J Mead,et al.  The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. , 2008, Blood.

[53]  J. Radich,et al.  Role of allogeneic stem cell transplantation in FLT3/ITD-positive AML. , 2006, Blood.

[54]  R. Hills,et al.  No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials. , 2005, Blood.

[55]  G. Ledderose,et al.  Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  C Anasetti,et al.  Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. , 2001, Blood.